Impact of dialysis dependence on survival for multiple myeloma with renal impairment: a multicenter study in China

被引:0
作者
Jian, Yuan [1 ]
Zhou, Huixing [1 ]
Xie, Weiwei [2 ]
Ren, Yuan [3 ]
Zhang, Zhiyao [1 ]
Yang, Guangzhong [1 ]
Geng, Chuanying [1 ]
Jia, Jing [1 ]
Chen, Wenming [1 ]
Huang, Wenrong [3 ]
Cen, Xinan [2 ]
Gao, Wen [1 ]
机构
[1] Capital Med Univ, Beijing Chaoyang Hosp, Myeloma Res Ctr Beijing, Dept Hematol, Beijing, Peoples R China
[2] Peking Univ First Hosp, Dept Hematol, Beijing, Peoples R China
[3] Gen Hosp Peoples Liberat Army, Med Ctr 5, Dept Hematol, Beijing, Peoples R China
来源
AMERICAN JOURNAL OF CANCER RESEARCH | 2023年 / 13卷 / 04期
基金
北京市自然科学基金;
关键词
Multiple myeloma; renal impairment; dialysis dependence; dialysis independence; survival; DIAGNOSIS; RECOVERY; POPULATION; MORTALITY; FAILURE; OUTCOMES; THERAPY;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Renal impairment (RI) is a very common complication of multiple myeloma (MM) with a negative impact on survival. Herein we retrospectively analyzed 334 MM patients with renal impairment at diagnosis from three hospi-tals in China. All 334 patients were divided into three groups, including dialysis dependence (n=43), dialysis inde-pendence (n=42), and without dialysis (n=249). Compared with dialysis independence and without dialysis groups, dialysis dependence group had the lowest overall hematologic response (48.8% vs. 97.6% vs. 77.1%, P<0.001) and overall renal response (0.0% vs. 97.6% vs. 72.7%, P<0.001), as well as the highest early mortality within 24 months (50.0% vs. 24.4% vs. 26.3%, P=0.006). Dialysis dependence group had similar progression-free survival (24 vs. 26 vs. 27 months, P=0.231) and significantly shorter overall survival (25 vs. 69 vs. 45 months, P=0.001). Dialysis dependence was independently associated with high mortality within 24 months and shorter overall survival. In conclusion, MM patients with dialysis dependence still tend to suffer a dismal disease course, including a high probability to suffer early mortality, worse hematological and renal response, as well as shorter survival. Dialysis independence could be very promising for survival improvement.
引用
收藏
页码:1571 / 1581
页数:11
相关论文
共 50 条
  • [31] Difficulties evaluating hematological response in patients with multiple myeloma and dialysis-dependent renal impairment
    Rekhtina, I. G.
    Mendeleeva, L. P.
    Soboleva, N. P.
    TERAPEVTICHESKII ARKHIV, 2019, 91 (07) : 70 - 74
  • [32] Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety
    Badros, A. Z.
    Vij, R.
    Martin, T.
    Zonder, J. A.
    Kunkel, L.
    Wang, Z.
    Lee, S.
    Wong, A. F.
    Niesvizky, R.
    LEUKEMIA, 2013, 27 (08) : 1707 - 1714
  • [33] Renal Impairment in Multiple Myeloma: Presenting Features in Different Departments
    Li, Ni
    Lv, Yongman
    Zeng, Hongbing
    He, Fan
    Yao, Ying
    He, Xiaofeng
    JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL SCIENCES, 2012, 32 (01) : 65 - 68
  • [34] Impact of High-Cut-Off Dialysis on Renal Recovery in Dialysis-Dependent Multiple Myeloma Patients: Results from a Case-Control Study
    Gerth, Hans U.
    Pohlen, Michele
    Goerlich, Dennis
    Thoelking, Gerold
    Kropff, Martin
    Berdel, Wolfgang E.
    Pavenstaedt, Hermann
    Brand, Marcus
    Kuempers, Philipp
    PLOS ONE, 2016, 11 (05):
  • [35] Modest survival benefits of autologous stem cell transplantation in multiple myeloma with renal impairment: a critical appraisal of the pre-antibody era
    Li, Yan
    Zhang, Xinyi
    Zou, Zhongqing
    Xiong, Yanqiu
    Gu, Xinyuan
    Zou, Ruiji
    Tan, Jing
    Zhang, Li
    Zheng, Yuhuan
    Niu, Ting
    CLINICAL AND EXPERIMENTAL MEDICINE, 2024, 24 (01)
  • [36] Effects of bortezomib on the prognosis of the newly-diagnosed multiple myeloma patients with renal impairment
    Yang, Guangzhong
    Wang, Jing
    Fu, Lina
    Shen, Man
    Jiang, Luan
    Zhang, Yong
    Huang, Zhongxia
    Gao, Wen
    Zhang, Lei
    Wu, Yin
    Li, Lihong
    Chen, Wenming
    AFRICAN JOURNAL OF PHARMACY AND PHARMACOLOGY, 2012, 6 (11): : 793 - 797
  • [37] Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment
    Bridoux, Frank
    Chen, Nianhang
    Moreau, Stephane
    Arnulf, Bertrand
    Moumas, Eric
    Abraham, Julie
    Desport, Estelle
    Jaccard, Arnaud
    Fermand, Jean Paul
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (01) : 173 - 182
  • [38] Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents
    Dimopoulos, M. A.
    Delimpasi, S.
    Katodritou, E.
    Vassou, A.
    Kyrtsonis, M. C.
    Repousis, P.
    Kartasis, Z.
    Parcharidou, A.
    Michael, M.
    Michalis, E.
    Gika, D.
    Symeonidis, A.
    Pouli, A.
    Konstantopoulos, K.
    Terpos, E.
    Kastritis, E.
    ANNALS OF ONCOLOGY, 2014, 25 (01) : 195 - 200
  • [39] Clinicopathologic predictors of renal response and survival in newly diagnosed multiple myeloma with renal injury: a retrospective study
    Wei, Wei
    Shi, Haotian
    Chen, Haimin
    Chen, Xiaoling
    Peng, Rong
    Yu, Wenjun
    Wu, Lixia
    Zhou, Nian
    Zhao, Wenhao
    Xu, Weiwei
    Zhou, Yan
    Yu, Jingjing
    Wei, Daolin
    Zhou, Fan
    CLINICAL AND EXPERIMENTAL MEDICINE, 2025, 25 (01)
  • [40] A non-invasive differential diagnostic model for light chain cast nephropathy in newly diagnosed multiple myeloma patients with renal involvement: a multicenter study
    Lin, Zi-Shan
    Qin, Ai-Bo
    Wang, Su-Xia
    Yu, Xiao-Juan
    Dong, Bao
    Xiong, Zu-Ying
    Chen, Meng-Hua
    Zhou, Fu-De
    Zhao, Ming-Hui
    JOURNAL OF NEPHROLOGY, 2021, 34 (04) : 1169 - 1177